Conduit Pharmaceuticals Inc. has announced a strategic partnership with Manoira to advance the development of AZD1656 and AZD5658 in the animal health sector. This collaboration aims to leverage cutting-edge reformulation expertise to accelerate human clinical programs while exploring commercial potential in the $15 billion animal health market. By entering this joint development agreement, Conduit seeks to generate cross-species insights and fast-track its therapeutic pipeline, all while maintaining full ownership of intellectual property and data. This partnership not only enhances Conduit's core human therapeutic offerings but also opens new revenue opportunities in the growing veterinary market, aligning with its strategy of innovative, high-return collaborations.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。